Amicus Therapeutics Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 511

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $5.77B

Amicus Therapeutics General Information

Description

Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 47 Hulfish Street
  • Princeton, NJ 08542
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 47 Hulfish Street
  • Princeton, NJ 08542
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amicus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
17. Merger/Acquisition 27-Apr-2026 $5.77B Completed Generating Revenue
16. Debt Refinancing 02-Oct-2023 Completed Generating Revenue
15. PIPE 29-Sep-2021 Completed Generating Revenue
14. 2PO 31-May-2019 Completed Generating Revenue
13. Debt - Acquisition 01-Sep-2018 Completed Generating Revenue
12. 2PO 16-Feb-2018 Completed Generating Revenue
11. 2PO 11-Jun-2015 Completed Generating Revenue
10. PIPE 03-Dec-2013 Completed Generating Revenue
9. PIPE 20-Nov-2013 $3M $290M Completed Generating Revenue
8. PIPE 30-Jul-2012 $18.6M $287M Completed Generating Revenue
To view Amicus Therapeutics’s complete valuation and funding history, request access »

Amicus Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people li
Drug Discovery
Princeton, NJ
511 As of 2025

San Diego, CA
 

Allschwil, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amicus Therapeutics Competitors (49)

One of Amicus Therapeutics’s 49 competitors is Avidity Biosciences, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avidity Biosciences Formerly VC-backed San Diego, CA
Idorsia Pharmaceuticals Corporation Allschwil, Switzerland
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Capricor Therapeutics Formerly VC-backed San Diego, CA
Xenon Pharmaceuticals Formerly VC-backed Burnaby, Canada
You’re viewing 5 of 49 competitors. Get the full list »

Amicus Therapeutics Patents

Amicus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260076951-A1 Methods of treating fabry disease in patients having renal impairment Pending 19-Sep-2024
WO-2026006625-A1 Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease Pending 26-Jun-2024
WO-2026006625-A9 Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease Pending 26-Jun-2024
WO-2025264978-A2 Recombinant alpha-galactosidase a proteins and gene therapy Pending 20-Jun-2024
WO-2025264978-A3 Recombinant alpha-galactosidase a proteins and gene therapy Pending 20-Jun-2024 C12Y302/01022
To view Amicus Therapeutics’s complete patent history, request access »

Amicus Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amicus Therapeutics Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
BlackRock Asset Manager Minority
CHL Medical Partners Venture Capital Minority
Canaan Partners Venture Capital Minority
Frazier Healthcare Partners PE/Buyout Minority
GSK Corporation Minority
You’re viewing 5 of 17 investors. Get the full list »

Amicus Therapeutics Acquisitions (4)

Amicus Therapeutics’s most recent deal was a Merger/Acquisition with Celenex for . The deal was made on 20-Sep-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Celenex 20-Sep-2018 Merger/Acquisition Buildings and Property
MiaMed 05-Jul-2016 Merger/Acquisition Buildings and Property
Scioderm 30-Sep-2015 Merger/Acquisition Pharmaceuticals
Callidus Biopharma 21-Nov-2013 Merger/Acquisition Drug Delivery
To view Amicus Therapeutics’s complete acquisitions history, request access »

Amicus Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

23.58 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Amicus Therapeutics’s complete esg history, request access »

Amicus Therapeutics Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Amicus Therapeutics Canada Toronto, Canada 2017
Amicus Biologics Philadelphia, PA 2002

Amicus Therapeutics FAQs

  • When was Amicus Therapeutics founded?

    Amicus Therapeutics was founded in 2002.

  • Where is Amicus Therapeutics headquartered?

    Amicus Therapeutics is headquartered in Princeton, NJ.

  • What is the size of Amicus Therapeutics?

    Amicus Therapeutics has 511 total employees.

  • What industry is Amicus Therapeutics in?

    Amicus Therapeutics’s primary industry is Drug Discovery.

  • Is Amicus Therapeutics a private or public company?

    Amicus Therapeutics is a Private company.

  • What is the current valuation of Amicus Therapeutics?

    The current valuation of Amicus Therapeutics is .

  • What is Amicus Therapeutics’s current revenue?

    The current revenue for Amicus Therapeutics is .

  • How much funding has Amicus Therapeutics raised over time?

    Amicus Therapeutics has raised $1.28B.

  • Who are Amicus Therapeutics’s investors?

    BlackRock, CHL Medical Partners, Canaan Partners, Frazier Healthcare Partners, and GSK are 5 of 17 investors who have invested in Amicus Therapeutics.

  • Who are Amicus Therapeutics’s competitors?

    Avidity Biosciences, Idorsia Pharmaceuticals, Sangamo Therapeutics, Capricor Therapeutics, and Xenon Pharmaceuticals are some of the 49 competitors of Amicus Therapeutics.

  • When was Amicus Therapeutics acquired?

    Amicus Therapeutics was acquired on 27-Apr-2026.

  • Who acquired Amicus Therapeutics?

    Amicus Therapeutics was acquired by BioMarin Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process